These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9682397)

  • 1. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
    Durbin AP; Wyatt LS; Siew J; Moss B; Murphy BR
    Vaccine; 1998 Aug; 16(13):1324-30. PubMed ID: 9682397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
    Durbin AP; Cho CJ; Elkins WR; Wyatt LS; Moss B; Murphy BR
    J Infect Dis; 1999 Jun; 179(6):1345-51. PubMed ID: 10228053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.
    Wyatt LS; Shors ST; Murphy BR; Moss B
    Vaccine; 1996 Oct; 14(15):1451-8. PubMed ID: 8994321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts.
    Skiadopoulos MH; Tao T; Surman SR; Collins PL; Murphy BR
    Vaccine; 1999 Oct; 18(5-6):503-10. PubMed ID: 10519940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
    Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
    Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
    Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
    J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.
    Mason JN; Elbahesh H; Russell CJ
    J Virol; 2013 May; 87(10):5959-69. PubMed ID: 23514887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates.
    Bukreyev A; Huang Z; Yang L; Elankumaran S; St Claire M; Murphy BR; Samal SK; Collins PL
    J Virol; 2005 Nov; 79(21):13275-84. PubMed ID: 16227250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.
    Lee MS; Greenberg DP; Yeh SH; Yogev R; Reisinger KS; Ward JI; Blatter MM; Cho I; Holmes SJ; Cordova JM; August MJ; Chen W; Mehta HB; Coelingh KL; Mendelman PM
    J Infect Dis; 2001 Oct; 184(7):909-13. PubMed ID: 11509996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys.
    Tang RS; Mahmood K; Macphail M; Guzzetta JM; Haller AA; Liu H; Kaur J; Lawlor HA; Stillman EA; Schickli JH; Fouchier RA; Osterhaus AD; Spaete RR
    Vaccine; 2005 Feb; 23(14):1657-67. PubMed ID: 15705469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.
    Skiadopoulos MH; Surman SR; Riggs JM; Collins PL; Murphy BR
    J Virol; 2001 Nov; 75(21):10498-504. PubMed ID: 11581420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
    Tao T; Skiadopoulos MH; Durbin AP; Davoodi F; Collins PL; Murphy BR
    Vaccine; 1999 Mar; 17(9-10):1100-8. PubMed ID: 10195620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.
    Durbin AP; Skiadopoulos MH; McAuliffe JM; Riggs JM; Surman SR; Collins PL; Murphy BR
    J Virol; 2000 Aug; 74(15):6821-31. PubMed ID: 10888621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection.
    Spriggs MK; Collins PL; Tierney E; London WT; Murphy BR
    J Virol; 1988 Apr; 62(4):1293-6. PubMed ID: 2831389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys.
    Hall SL; Stokes A; Tierney EL; London WT; Belshe RB; Newman FC; Murphy BR
    Virus Res; 1992 Mar; 22(3):173-84. PubMed ID: 1320790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.
    Englund JA; Karron RA; Cunningham CK; Larussa P; Melvin A; Yogev R; Handelsman E; Siberry GK; Thumar B; Schappell E; Bull CV; Chu HY; Schaap-Nutt A; Buchholz U; Collins PL; Schmidt AC;
    Vaccine; 2013 Nov; 31(48):5706-12. PubMed ID: 24103895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters.
    Afroz S; Saul S; Dai J; Surman S; Liu X; Park HS; Le Nouën C; Lingemann M; Dahal B; Coleman JR; Mueller S; Collins PL; Buchholz UJ; Munir S
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2316376121. PubMed ID: 38861603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.